- Home
- HRMY vs NMM Comparison
HRMY vs NMM Comparison
Compare HRMY & NMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRMY | NMM |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.3B |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | HRMY | NMM |
|---|---|---|
| Price | $37.37 | $56.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $51.33 | N/A |
| AVG Volume (30 Days) | ★ 656.4K | 99.3K |
| Earning Date | 02-24-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 0.36% |
| EPS Growth | ★ 50.44 | N/A |
| EPS | 3.17 | ★ 8.91 |
| Revenue | $825,944,000.00 | ★ $1,311,114,000.00 |
| Revenue This Year | $23.11 | N/A |
| Revenue Next Year | $16.15 | $15.22 |
| P/E Ratio | $11.85 | ★ $6.22 |
| Revenue Growth | ★ 21.13 | N/A |
| 52 Week Low | $25.52 | $28.37 |
| 52 Week High | $40.93 | $56.44 |
Technical Indicators
Market Signals| Indicator | HRMY | NMM |
|---|---|---|
| Relative Strength Index (RSI) | 51.18 | 68.49 |
| Support Level | $35.42 | $50.93 |
| Resistance Level | $38.11 | $52.65 |
| Average True Range (ATR) | 1.03 | 1.27 |
| MACD | -0.36 | 0.40 |
| Stochastic Oscillator | 44.98 | 91.10 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About NMM Navios Maritime Partners LP
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.